A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer

Agaylan, Ashraf; Binder, Daniel; Sauer, Markus; Neuweiler, Hannes; Meyer, Oliver; Kiesewetter, H.; Salama, Abdulgabar

doi:10.1002/cncr.23057

Cited by 3 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, there are many studies in the literature on the role of serum anti-p53 Abs in the early diagnosis of lung cancer as well as other cancer types. While some studies practice on panels of other antigens in addition to p53, some studies practice the sensitivity of anti-p53 Abs assay methods (13). Maddau et al (12) detected p53 expression at 51.7% of 180 NSCLC patients.…”

Section: Discussionmentioning

confidence: 99%

The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer

Hasbek

Doǧan²,

Sarı³

et al. 2016

Mirt

View full text Add to dashboard Cite

Objective:Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUVmax), SUVave, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size.Methods:Serum anti-p53 Ab level was studied in three groups. Patients who underwent 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent 18F-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN=pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers.Results:Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p<0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUVmax, SUVave, TLG, tumor volume and tumor size of patients with lung cancer (p>0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p>0.05).Conclusion:It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion.

show abstract

Section: Discussionmentioning

confidence: 99%

The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer

Hasbek

Doǧan²,

Sarı³

et al. 2016

Mirt

View full text Add to dashboard Cite

show abstract

“…Furthermore, ELISA shows a high specificity, but a low sensitivity for serum antibody detection and novel and more sensitive methods have been developed, such as the particle agglutination assay [25]. However, ELISA still retains its value for diagnostic accuracy and easy performance in routine diagnostic procedures [26].…”

Section: Methodsmentioning

confidence: 99%

Serum p53 antibody detection in patients with impaired lung function

Mattioni¹,

Chinzari²,

Soddu³

et al. 2013

BMC Cancer

View full text Add to dashboard Cite

BackgroundTP53 gene mutations can lead to the expression of a dysfunctional protein that in turn may enable genetically unstable cells to survive and change into malignant cells. Mutant p53 accumulates early in cells and can precociously induce circulating anti-p53 antibodies (p53Abs); in fact, p53 overexpression has been observed in pre-neoplastic lesions, such as bronchial dysplasia, and p53Abs have been found in patients with Chronic Obstructive Pulmonary Disease, before the diagnosis of lung and other tobacco-related tumors.MethodsA large prospective study was carried out, enrolling non-smokers, ex-smokers and smokers with or without the impairment of lung function, to analyze the incidence of serum p53Abs and the correlation with clinicopathologic features, in particular smoking habits and impairment of lung function, in order to investigate their possible role as early markers of the onset of lung cancer or other cancers. The p53Ab levels were evaluated by a specific ELISA in 675 subjects.ResultsData showed that significant levels of serum p53Abs were present in 35 subjects (5.2%); no difference was observed in the presence of p53Abs with regard to age and gender, while p53Abs correlated with the number of cigarettes smoked per day and packs-year. Furthermore, serum p53Abs were associated with the worst lung function impairment. The median p53Ab level in positive subjects was 3.5 units/ml (range 1.2 to 65.3 units/ml). Only fifteen positive subjects participated in the follow-up, again resulting positive for serum p53Abs, and no evidence of cancer was found in these patients.ConclusionThe presence of serum p53Abs was found to be associated with smoking level and lung function impairment, both risk factors of cancer development. However, in our study we have not observed the occurrence of lung cancer or other cancers in the follow-up of positive subjects, therefore we cannot directly correlate the presence of serum p53Abs with cancer risk.

show abstract

“…The titles and abstracts of 7173 articles were screened and a total of 7079 were excluded based on the exclusion criteria described above. Of the remaining 94 full-text articles, 10 were excluded because a disease control was used 14–23 , 9 were excluded because they did not have satisfied outcomes 24–32 , and 8 were excluded because of their small sample size ( n < 10) 33–40 , Ultimately, 67 articles were included in this systematic review evaluating the diagnostic performance of TAAbs in serum or plasma for LC detection (Tables 1 and 2).…”

Section: Study Identification and Literature Searchmentioning

confidence: 99%

Autoantibodies as diagnostic biomarkers for lung cancer: A systematic review

Yang

Ren

et al. 2019

Cell Death Discov.

View full text Add to dashboard Cite

Lung cancer (LC) accounts for the largest number of tumor-related deaths worldwide. As the overall 5-year survival rate of LC is associated with its stages at detection, development of a cost-effective and noninvasive cancer screening method is necessary. We conducted a systematic review to evaluate the diagnostic values of single and panel tumor-associated autoantibodies (TAAbs) in patients with LC. This review included 52 articles with 64 single TAAbs and 19 with 20 panels of TAAbs. Enzyme-linked immunosorbent assays (ELISA) were the most common detection method. The sensitivities of single TAAbs for all stages of LC ranged from 3.1% to 92.9% (mean: 45.2%, median: 37.1%), specificities from 60.6% to 100% (mean: 88.1%, median: 94.9%), and AUCs from 0.416 to 0.990 (mean: 0.764, median: 0.785). The single TAAb with the most significant diagnostic value was the autoantibody against human epididymis secretory protein (HE4) with the maximum sensitivity 91% for NSCLC. The sensitivities of the panel of TAAbs ranged from 30% to 94.8% (mean: 76.7%, median: 82%), specificities from 73% to 100% (mean: 86.8%, median: 89.0%), and AUCs from 0.630 to 0.982 (mean: 0.821, median: 0.820), and the most significant AUC value in a panel (M13 Phage 908, 3148, 1011, 3052, 1000) was 0.982. The single TAAb with the most significant diagnostic calue for early stage LC, was the autoantibody against Wilms tumor protein 1 (WT1) with the maximum sensitivity of 90.3% for NSCLC and its sensitivity and specificity in a panel (T7 Phage 72, 91, 96, 252, 286, 290) were both above 90.0%. Single or TAAbs panels may be useful biomarkers for detecting LC patients at all stages or an early-stage in high-risk populations or health people, but the TAAbs panels showed higher detection performance than single TAAbs. The diagnostic value of the panel of six TAAbs, which is higher than the panel of seven TAAbs, may be used as potential biomarkers for the early detection of LC and can probably be used in combination with low-dose CT in the clinic.

show abstract

A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer

Abstract: The newly developed assay was easy to perform and had sensitivity superior to that of the currently available p53 ELISAs.

Cited by 3 publications

References 15 publications

The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer

The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer

Serum p53 antibody detection in patients with impaired lung function

Autoantibodies as diagnostic biomarkers for lung cancer: A systematic review

Contact Info

Product

Resources

About